Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIMI/AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a smaller reporting biotechnology issuer focused on immuno-pharma therapeutics. AIM ImmunoTech files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other forms that document its financial condition, governance decisions and material events.
For investors tracking AIM ImmunoTech’s development-stage biotechnology business, the company’s periodic reports are central. The Form 10-K and Form 10-Q filings describe its status as a smaller reporting company, summarize its focus on therapeutics for cancers, immune disorders and viral diseases, and provide financial statements that reflect revenues and net losses consistent with a research-focused enterprise. A Form 12b-25 (Notification of Late Filing) for the quarter ended September 30, 2025 explains delays in completing the required review, outlines the expectation to file within the permitted extension period and describes anticipated changes in revenues, net loss and loss per share compared to prior-year periods.
AIM ImmunoTech also uses Form 8-K to report material events. Examples include furnishing a corporate presentation under Regulation FD, disclosing NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance, and filing its Certificate of Incorporation as amended and restated as an exhibit. These current reports help investors understand exchange listing issues, governance documents and other significant developments beyond routine financial reporting.
Proxy statements on Schedule 14A, such as the definitive proxy for the 2025 Annual Meeting of Stockholders, provide detail on board elections, advisory votes on executive compensation, auditor ratification and the company’s use of scaled disclosure obligations as a smaller reporting company. Voting results for proposals, reported via Form 8-K, show how stockholders have voted on directors, compensation matters and the frequency of advisory votes.
On Stock Titan, AIM ImmunoTech’s filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. This helps users quickly identify information on topics such as financial performance trends, exchange compliance, governance decisions and material agreements, while still allowing access to the full original filings for detailed review. Form 4 insider transaction data, when filed, can also be monitored alongside these core disclosures to give a fuller picture of corporate activity.
AIM ImmunoTech Inc. entered into definitive agreements for a registered direct offering and concurrent private placement totaling approximately $2.65 million in gross proceeds. The company is selling 2,554,119 registered shares at $0.5189 per share and matching unregistered shares or pre-funded warrants, plus Class J warrants for up to 10,216,476 shares.
The transaction also includes pre-funded warrants at a $0.001 exercise price and Class J warrants exercisable at $0.5189 per share following stockholder approval. If all pre-funded and Class J warrants are exercised for cash, AIM could receive about $5.3 million in additional gross proceeds. Net proceeds are earmarked for clinical drug manufacturing, current and planned Phase 3 trial activities, and working capital.
AIM ImmunoTech Inc. entered into definitive agreements for a registered direct offering and concurrent private placement totaling approximately $2.65 million in gross proceeds. The company is selling 2,554,119 registered shares at $0.5189 per share and matching unregistered shares or pre-funded warrants, plus Class J warrants for up to 10,216,476 shares.
The transaction also includes pre-funded warrants at a $0.001 exercise price and Class J warrants exercisable at $0.5189 per share following stockholder approval. If all pre-funded and Class J warrants are exercised for cash, AIM could receive about $5.3 million in additional gross proceeds. Net proceeds are earmarked for clinical drug manufacturing, current and planned Phase 3 trial activities, and working capital.
AIM ImmunoTech Inc. updated its corporate bylaws to change how most shareholder proposals are approved. Effective June 9, 2026, proposals other than director elections will pass with a majority of the votes cast, meaning only votes "for" or "against" are counted and abstentions and broker non-votes are excluded. Previously, these matters required approval by a majority in voting power of the shares present and entitled to vote. The amendment is detailed in an attached bylaw amendment filed as an exhibit.
AIM ImmunoTech Inc. updated its corporate bylaws to change how most shareholder proposals are approved. Effective June 9, 2026, proposals other than director elections will pass with a majority of the votes cast, meaning only votes "for" or "against" are counted and abstentions and broker non-votes are excluded. Previously, these matters required approval by a majority in voting power of the shares present and entitled to vote. The amendment is detailed in an attached bylaw amendment filed as an exhibit.
AIM ImmunoTech Inc. is offering 2,554,119 registered shares of Common Stock at $0.5189 per share. The prospectus supplement describes a concurrent private placement to accredited investors for 771,503 unregistered shares, pre-funded warrants to purchase 1,782,616 shares and Class J warrants to purchase up to 10,216,476 shares. Net proceeds from the registered offering are estimated at approximately $1.2 million after placement agent fees and estimated offering expenses; proceeds are intended to support a planned Phase 3 trial for Ampligen, manufacture clinical drug supply and for working capital. The Common Warrants become exercisable only upon the Stockholder Approval Date and will expire five years thereafter; the Pre-Funded Warrants are exercisable immediately at $0.001 per share. The offering is on a reasonable best efforts basis with no minimum and is subject to lock-ups, placement agent compensation (cash fees and warrants), and NYSE American continued-listing risks.
AIM ImmunoTech Inc. is offering 2,554,119 registered shares of Common Stock at $0.5189 per share. The prospectus supplement describes a concurrent private placement to accredited investors for 771,503 unregistered shares, pre-funded warrants to purchase 1,782,616 shares and Class J warrants to purchase up to 10,216,476 shares. Net proceeds from the registered offering are estimated at approximately $1.2 million after placement agent fees and estimated offering expenses; proceeds are intended to support a planned Phase 3 trial for Ampligen, manufacture clinical drug supply and for working capital. The Common Warrants become exercisable only upon the Stockholder Approval Date and will expire five years thereafter; the Pre-Funded Warrants are exercisable immediately at $0.001 per share. The offering is on a reasonable best efforts basis with no minimum and is subject to lock-ups, placement agent compensation (cash fees and warrants), and NYSE American continued-listing risks.
AIM ImmunoTech Inc. has filed an S-1 to register up to 31,287,933 shares of common stock for resale by existing holders of Class H and Class I warrants and related placement agent warrants. AIM will not receive proceeds from these stockholder sales, though full cash exercise of the warrants could bring in about $14.5 million for general corporate purposes and working capital.
The filing highlights substantial potential dilution, as common shares could rise from 24,328,623 to 55,616,556 if all registered warrants are exercised. AIM describes its focus on developing Ampligen for late-stage pancreatic cancer and other oncology and antiviral indications, while also warning about NYSE American listing risks, possible penny stock status, and significant stock price volatility.
AIM ImmunoTech Inc. has filed an S-1 to register up to 31,287,933 shares of common stock for resale by existing holders of Class H and Class I warrants and related placement agent warrants. AIM will not receive proceeds from these stockholder sales, though full cash exercise of the warrants could bring in about $14.5 million for general corporate purposes and working capital.
The filing highlights substantial potential dilution, as common shares could rise from 24,328,623 to 55,616,556 if all registered warrants are exercised. AIM describes its focus on developing Ampligen for late-stage pancreatic cancer and other oncology and antiviral indications, while also warning about NYSE American listing risks, possible penny stock status, and significant stock price volatility.
AIM ImmunoTech Inc. filed an update describing new investor-focused materials on its lead drug candidate Ampligen for Ebola virus disease preparedness. The company released a Virtual Investor “What This Means” video segment and an Ebola-focused investor presentation reviewing previously published preclinical data and regulatory groundwork.
Management discusses the ongoing Bundibugyo Ebola outbreak, the lack of approved targeted therapies or vaccines for this strain, and Ampligen’s immune‑modulating mechanism as a PAMP‑restricted TLR3 agonist. The materials highlight Biosafety Level 4 preclinical findings showing 100% survival with early Ampligen administration in a lethal Ebola mouse model and note orphan drug designations from U.S. and European regulators, while emphasizing that significant additional testing and human trials are still required.
AIM ImmunoTech Inc. filed an update describing new investor-focused materials on its lead drug candidate Ampligen for Ebola virus disease preparedness. The company released a Virtual Investor “What This Means” video segment and an Ebola-focused investor presentation reviewing previously published preclinical data and regulatory groundwork.
Management discusses the ongoing Bundibugyo Ebola outbreak, the lack of approved targeted therapies or vaccines for this strain, and Ampligen’s immune‑modulating mechanism as a PAMP‑restricted TLR3 agonist. The materials highlight Biosafety Level 4 preclinical findings showing 100% survival with early Ampligen administration in a lethal Ebola mouse model and note orphan drug designations from U.S. and European regulators, while emphasizing that significant additional testing and human trials are still required.
AIM ImmunoTech Inc. ownership disclosure: three related reporting persons (Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC) filed a joint Schedule 13G describing potential beneficial ownership tied to a Securities Purchase Agreement executed May 20, 2026.
The filing states that 1,538,462 shares of Common Stock may be issuable to Intracoastal at closing, representing approximately 8.5% based on 16,505,501 shares outstanding as of May 20, 2026. It also discloses an Intracoastal Warrant for 3,076,924 shares subject to stockholder approval and a 4.99% exercise blocker. As of close of business on May 27, 2026, the filing reports the reporting persons may be deemed to beneficially own 0 shares.
AIM ImmunoTech Inc. ownership disclosure: three related reporting persons (Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC) filed a joint Schedule 13G describing potential beneficial ownership tied to a Securities Purchase Agreement executed May 20, 2026.
The filing states that 1,538,462 shares of Common Stock may be issuable to Intracoastal at closing, representing approximately 8.5% based on 16,505,501 shares outstanding as of May 20, 2026. It also discloses an Intracoastal Warrant for 3,076,924 shares subject to stockholder approval and a 4.99% exercise blocker. As of close of business on May 27, 2026, the filing reports the reporting persons may be deemed to beneficially own 0 shares.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.